PRINCETON, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD)
announced today that Deborah Tanner will be promoted to Corporate Senior Vice
President and President of Central Laboratory Services. She will also be named
a member of the company's Global Leadership Council. Tanner succeeds Steve
Sullivan, who is assuming the role of CEO for Harlan Sprague Dawley, Inc.
"Deborah brings a wealth of scientific, regulatory, industry, and business
experience to her new role as leader of one of Covance's top-performing
business units, and we look forward to her valuable perspectives as a member
of the executive leadership team," said Joe Herring, Covance Chairman and
Chief Executive Officer. "Her promotion exemplifies our solid succession
planning and allows us to recognize an outstanding performer. We also thank
Steve for his leadership and contributions to the success of Covance."
Tanner's 19-year career at Covance began in 1987, when she joined what was
then called Hazleton Laboratories in Madison, Wisconsin, as a Quality
Assurance Manager. She subsequently held various managerial positions in
metabolism and bioanalytical chemistry and headed Global Marketing for
Covance's Early Development business. Tanner then spent two years in
Harrogate, UK, leading Analytical Services for Labs Europe. After 14 years in
the Early Development businesses, she was promoted to Vice President of Global
Clinical Trial Management Services and Operations for Central Laboratories,
eventually assuming additional responsibilities as Site Head for the
Indianapolis facility.
"Becoming the leader of Covance Central Laboratories at this stage of its
development is very exciting," Deborah Tanner said. "Over the past several
years, we have made significant contributions to the success of Covance,
including record new orders and market share gains that have translated into
accelerated growth for the company. We will continue to focus our efforts on
driving Operational and Service Excellence by providing high-quality data,
outstanding project management of global clinical trials, and helping our
clients maximize their R&D investment."
Tanner has dual undergraduate degrees in Life Sciences/Chemistry and
Business Administration and Accounting as well as a Master of Business
Administration degree from the University of Wisconsin in Madison.
Covance, with headquarters in Princeton, New Jersey, is one of the world's
largest and most comprehensive drug development services companies with annual
revenues greater than $1 billion, global operations in more than 20 countries,
and more than 7,300 employees worldwide. Information on Covance's products
and services, recent press releases, and SEC filings can be obtained through
its website at http://www.covance.com.